COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma
Axel Hauschild(University Hospital Schleswig-Holstein), John M. Kirkwood(UPMC Hillman Cancer Center), Ru‐Rong Ji(Duke University), Jeffrey J. Legos(Novartis (United States)), Jacob Schachter, P. Zhang(Novartis (United States)), Marta Nyakas(Oslo University Hospital), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), Georgina V. Long(The University of Sydney), Laurent Mortier, Victoria Atkinson(The University of Queensland), Bijoyesh Mookerjee(Novartis (United States)), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University Hospital of Zurich), Andrew Haydon(The Alfred Hospital), Caroline Robert(Institut Gustave Roussy), Mario Mandalà(University of Perugia)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k